A study found that patients with elevated levels of two specific proteins were more likely to develop severe neo crown symptoms,media BGR reported. Drugs designed to block these proteins are currently being tested for FDA approval.
One of the special aspects of the new coronavirus is that its effects on people are completely different. Some people may test positive and have no symptoms, while others may have long-term sequelae. What’s more, men seem to be at higher risk than women, while children seem to be less affected by the virus. It took medical experts some time to fully understand the extent to which the new coronavirus affects different populations.
Researchers have since determined that adults with existing complications such as chronic heart disease, diabetes, lung disease, kidney disease and asthma are more likely than others to ensure severe coronavirus symptoms. In September, researchers at Mount Sinai revealed that various markers could be tested to help doctors more accurately determine which patients are likely to be affected by the full impact of the new coronavirus and then treat them accordingly.
In particular, the researchers found that patients were more likely than others to die from the new coronavirus when levels of two proteins in their blood — IL-6 and TNF-a — increased.
The study suggests that these cytokines should be monitored during the treatment of COVID-19 patients to help select specific drugs that should be entered into clinical trials and be able to target them.
The team said serum IL-6 and TNF-alpha levels should be considered in the management and treatment of COVID-19 patients.
They also recommend that patients with high levels of IL-6 and TNF-alpha be evaluated to jointly block pathogenic inflammation of the disease.
Part of the study is as follows:
In addition to IL-6, several cytokines have been shown to rise in CRS and cause tissue damage. TNF-alpha is important in almost all acute inflammatory responses and is an amplifier of inflammation. TNF-alpha blocking has been used to treat more than a dozen different autoimmune inflammatory diseases, suggesting that this may be a potential treatment for reducing organ damage in COVID-19 patients.
Hopefully and interestingly, the new crown drug, which is currently undergoing FDA approval testing, has been designed to block IL-6 and TNF-alpha proteins.
As for how to prevent the occurrence of new coronavirus in the first place, the research work of effective new coronavirus is still ongoing. So far, there are potential candidates for clinical trials, and Dr. Anthony Folch, the chief infectious disease expert in the United States, said recently that he would know by November whether the vaccine would be approved by the FDA.
Meanwhile, Mr. Fucci said last week that while it was important to be vigilant about security measures for the new coronavirus, it was important to remind people that the pandemic would eventually end. “This outbreak is going to end,” Fucci said. “We’re going to get a vaccine. If we combine vaccines with prudent public health measures, we can put all this behind us. “